
|Videos|December 11, 2020
Management of high-risk NMIBC: Options for treatment expand
Author(s)Urology Times staff
“As urologists, we all need to start speaking in risk stratification criteria,” says Katie Murray, DO.
Advertisement
In this video, Katie Murray, DO, shares her takeaways from a discussion at the 2020 Society of Urologic Oncology annual meeting titled, Optimizing Management of High Risk NMIBC – Case-Based Discussion, for which she served as a panelist. Murray is an assistant professor of surgery-urology at the University of Missouri, Columbia.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
4
FDA approves first-line Zenflow system for the treatment of BPH
5


















